A Phase I, Randomized, Double-blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of ASC50 Tablets in Healthy Adult Participants and Adult Participants With Mild to Moderate Plaque Psoriasis
Latest Information Update: 25 Jun 2025
At a glance
- Drugs ASC 50 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Ascletis
Most Recent Events
- 17 Jun 2025 According to the Ascletis Media Release, comoany announced that first patient has been dosed in this trial.
- 17 Jun 2025 Status changed from planning to recruiting, according to the Ascletis Media Release.
- 06 Jun 2025 New trial record